Topoisomerase I (TopoI), an established anticancer target, is an enzyme producing a single-strand DNA break during transcription. Several noncamptothecin TopoI inhibitors have been identified. One of these, ARC-111, was compared with two clinically used camptothecins, topotecan and irinotecan/SN-38. In mouse and human bone marrow colony formation [colony-forming units granulocytemacrophage (CFU-GM)] assays, the IC 90 values were 519 and 331 nmol/L for topotecan and SN-38 mouse CFU-GM and were 19 and 26 nmol/L for human CFU-GM, giving mouse to human differentials of 28-and 13-fold. ARC-111 produced IC 90 values of 28 nmol/L in mouse and 6.2 nmol/L in human CFU-GM, thus only a 4.5-fold differential between species. Human bone marrow CFU-GM was more sensitive to topotecan than were several human cancer cell lines, but ARC-111 cytotoxicity was similar for human bone marrow CFU-GM and the seven human tumor cell lines tested. In HCT-116 xenografts, tumor growth delays (TGD) were 17 days for irinotecan and 20 days for ARC-111. In HT-29 xenografts, the TGD was 9 days for both irinotecan and ARC-111. Both ARC-111 and docetaxel had a TGD of 21 days in NCI-H460
Introduction
Topoisomerase I (TopoI) is an essential enzyme in mammalian cells (1, 2) . TopoI produces a single-strand break in DNA allowing relaxation of DNA for transcription. The single-strand break is then religated, restoring the DNA double strands (3 -5) . DNA topoisomerase enzymes regulate the topological state of DNA; thus, they control the cellular processes that involve DNA (6) . Topoisomerase activity is crucial for initiation and elongation during DNA synthesis, for the proper separation of sister chromatids during mitosis, and for RNA transcription (7 -16) . TopoI associates preferentially with transcriptionally active genes and is thought to be involved in relaxing supercoils introduced by RNA polymerase during RNA transcription (17 -19) .
The TopoI-targeted drugs topotecan and irinotecan stabilize the covalent TopoI-DNA complex, thereby preventing religation ( Fig. 1 ; refs. 20 -22) . The TopoI reaction intermediate consists of the enzyme covalently linked to a nicked DNA molecule. This assembly is known as a ''cleavable complex.'' Covalently bound TopoI-DNA complexes can be recovered intact and purified and used to determine the preferred sites of enzymatic cleavage (23 -25) .
TopoI inhibitors exhibit S-phase cytotoxicity and G 2 -M cell cycle arrest. A proposed mechanism for the arrest and subsequent S-phase cytotoxicity involves a replication fork collision between an advancing replication fork and the inhibitor-trapped TopoI-DNA cleavable complex, which triggers replication fork arrest and breakage to generate a DNA double-strand break and a covalent TopoI-DNA complex (26, 27) . This collision is responsible for the G 2 -M arrest and activation of DNA damage signals including nuclear factor-nB activation, p53 up-regulation, replication protein A phosphorylation, Chk1 phosphorylation, and ATM/ATR activation (28, 29) . Elevated TopoI levels in tumors make TopoI inhibitors attractive antitumor agents (30, 31) . When inhibited, TopoI is down-regulated and targeted by the ubiquitin/proteasome pathway (32 -34) . Inhibitor-TopoI-DNA cleavable complexes are rapidly conjugated with SUMO, an ubiquitin-like protein, by UBC9, perhaps as a repair response (35, 36) .
Despite clinical success, there are several problems with the camptothecin anticancer agents, topotecan and irinotecan. A major limitation is the presence of the E-ring-opened form, which is in chemical equilibrium with the camptothecin lactone form. The E-ring-opened carboxylate form has less than 10% of the TopoI-inhibiting potency of the lactone form and is completely inactive in cell culture perhaps because this negatively charged form is unable to cross the cell membrane (37, 38) . Furthermore, although the lactone form can freely enter cells via passive diffusion across cell membranes, their intracellular concentration is greatly reduced by efflux pumps in a wide variety of tissues (5, 39 -43) . Multidrug resistance (MDR) results from drug efflux by the well-characterized P-glycoprotein for which both topotecan and irinotecan are substrates (40) . Additionally, camptothecins are substrates for the pump known as breast cancer-resistant protein (BCRP; refs. 40 -43) .
ARC-111 is related to nitidine and fagaronine, benzo[c] phenanthridine alkaloids, which show good antitumor potency. Both compounds are TopoI inhibitors (43) . Synthetic compounds such as ARC-111 are as potent as camptothecin in inhibiting DNA reannealing by purified human TopoI and are more potent than irinotecan in many human tumor xenograft efficacy models (44 -47) . An extensive structure-activity relationship was conducted on the dibenzo[c,h][1,6]naphthyridin-6-one family of compounds, which elucidated structural features associated with potent TopoI-targeting activity and candidates with suitable pharmaceutical properties (48) . Enhanced TopoItargeting, cytotoxic potency, and robust antitumor activity were associated with (a) methoxy substitutents at both 2-and 3-positions of the A-ring, (b) an 8,9-methylenedioxy moiety with in the D-ring, and (c) hetero-atom substitution adjacent to the benzo ring that incorporates the methylenedioxy substituent. These compounds are not substrates for MDR1 or BCRP efflux and are able to evade clearance by those pathways. ARC-111 was selected for in-depth study in cell-based and efficacy models (47 -49) .
Bone marrow is critically sensitive to many antineoplastic agents. TopoI inhibitors kill rapidly dividing bone marrow progenitor cells as well as tumor cells, resulting in acute reversible neutropenia and thrombocytopenia 4 to 20 days later (50) . A goal during preclinical development is to predict toxicity of new agents to bone marrow and to determine whether bone marrow progenitor cells will be more or less sensitive to the agent than human malignant cells.
Bone marrow colony-forming units granulocyte-macrophage (CFU-GM) assays comparing the sensitivity of bone marrow cells across species are useful in predicting the blood levels of an agent that might be achieved with acceptable toxicity in patients compared with blood levels tested in preclinical efficacy and safety study species. Mouse bone marrow is less sensitive to many cytotoxic agents than is human bone marrow, allowing blood levels in preclinical efficacy testing that cannot be achieved in patients. Generally, human and canine bone marrow may have similar sensitivity to TopoI inhibitors, and murine bone marrow is less sensitive to these compounds (49 -52) . The difference in sensitivity between murine and human bone marrow progenitor cells to TopoI inhibitors may explain, in part, why curative doses/blood levels of topotecan and 9-amino-camptothecin in mice with human tumor xenografts are not achievable in patients (52) . An efficacious level of a compound with smaller or no differential in bone marrow progenitor sensitivity among species may have a better potential for reaching similar blood levels in patients as in mice. Pessina (50) went further to suggest that through use of the ratio of mouse/human CFU-GM IC 90 values and the mouse maximum tolerated dose that the human maximum tolerated dose of a compound could be predicted and thus the potential for achieving a therapeutic blood level in patients estimated.
The current report describes and compares the bone marrow CFU-GM and tumor cell CFU activity of TopoI inhibitors, topotecan, irinotecan/SN-38, and ARC-111 and examines the activity of these compounds in several human tumor xenograft models.
Material and Methods

Materials
The purity and chemical identity of ARC-111 [8,9- 
]naphthyridin-6-one] was confirmed (44 -48) . Topotecan, irinotecan, and SN-38 were used as purchased from LKT Laboratories. ARC-111 was prepared as a 100 Amol/L stock solution in D5W (5% dextrose, aqueous, injection USP, B. Braun Medical). Aliquots (2 mL) were made for ARC-111 in sterile, capped polypropylene tubes and stored frozen at À20jC until use. For cell culture, topotecan and SN-38 were prepared as 10 mmol/L stock solutions in DMSO from Sigma. Aliquots (100 AL) were made for topotecan and SN-38 in sterile, capped Eppendorf tubes and stored frozen at À20jC until use.
For colony-forming assays, ARC-111 aliquots were thawed the day of the assay, and dilutions of 20 times the desired final concentration were prepared from the stock solutions in RPMI 1460/5% fetal bovine serum (FBS). Topotecan and SN-38 aliquots were thawed the day of the assay, and dilutions of 20 times the desired final concentration were prepared from a 1:1,000 of a 10 Amol/L stock solution (5 AL + 5 mL) in RPMI 1460/5% FBS.
Mouse Bone Marrow Male BALB/c mice were purchased from Charles River Laboratories at age 6 to 8 weeks and used for studies at age 7 to 10 weeks. The mice were housed four to eight per cage, had free access to tap water, and were fed a normal diet and were observed daily. The procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee in accordance with the Federal Animal Welfare Act (9 CFR, 1992) and were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility.
For bone marrow collection, naive mice were sacrificed by asphyxiation through inhalation of carbon dioxide. To ensure a sterility of the bone marrow, the sacrificed donor mouse was placed in a biological laminar flow hood and the whole body was sprayed with a 70% ethanol solution. A skin incision is made throughout the whole hind limb from midpoint of inguinal ligament to the medial side of the foot. The muscle and other connective tissues were removed and both tibias and the femurs were extracted. The bone medullary cavity was accessed by removing the epiphysis of the tibia or the femur located at the end of long bones. A blunt syringe needle (27 gauge) was inserted into the medullary cavity and the cavity was flushed with 2 mL sterile RPMI 1460/5% FBS until the color of bone shaft became pale, indicating removal of the bone marrow. The resulting cellular suspension was collected into a 50 mL conical bottom tube and kept on wet ice. Approximately 25 million cells were obtained from each mouse.
Bone Marrow CFU-GM Assay For mouse CFU-GM assays, freshly isolated mouse bone marrow cells were cultured in MethoCult, containing the cytokines rmSCF, rmIL-3, and rhIL-6 to assist growth (Stem Cell Technologies).
For human CFU-GM assays, viable human bone marrow cells (purchased as frozen vials from All Cells via Stem Cell Technologies) were prepared with a DNase treatment (Stem Cell Technologies) and then washed in a protocol described by the vendor and cultured. The culture medium used was MethoCult GF, containing the cytokines hSCF, hGM-CSF, and hIL-3 (Stem Cell Technologies).
Both human and mouse MethoCult media were received frozen in 100 mL volumes. On receipt, bottles were thawed overnight at 4jC and divided into 3 mL aliquots in sterile 15 mL tubes. The MethoCult media solidify at 37jC and were not warmed to greater than room temperature until cells and compounds are added immediately before transfer to 37jC. The MethoCult medium aliquots were refrozen at À20jC until thawing at 4jC overnight before the assay.
For experiments, 150 AL of 20Â concentration of the compounds, along with 150 AL of a suspension of mouse or human bone marrow cells, were added to the 3 mL tube of appropriate thawed MethoCult medium and vigorously mixed using a vortex mixer. Final cell concentrations were 4 Â 10 4 cells per plate for mouse cells and 8 Â 10 4 cells per plate for human cells. Tubes were then allowed to sit undisturbed for 10 to 15 min until the air bubbles dissipated. A blunt needle attached to a 3 mL syringe was used to collect 2.5 mL of the cell suspension, the air was voided from the syringe, and 1 mL was placed in the center of duplicate treatment-labeled 100 cm 2 culture dishes. Dishes were gently rotated to allow even coverage of the bottom surface of each dish, and dishes are placed in a 37jC incubator for colony formation for 13 days for mouse bone marrow and 15 days for human bone marrow. Colonies were defined as clusters containing z30 cells.
Human and mouse bone marrow progenitor cells were continuously exposed to a concentration range of ARC-111, topotecan, or SN-38 in three independent CFU-GM colony formation experiments. The compound concentrations were made in half-log intervals covering 5 logs (10 concentrations). The IC 50 and IC 90 values were expressed as the means with lower and upper 95% confidence intervals in nanomolar concentrations.
Tumor Cell Survival CFU Assay The MDA-MB-231, HCT-116, HT-29, NCI-H460, and RPMI-8226 cell lines were purchased from the American Type Culture Collection. The KB3-1 and KB-V1 cell lines were a kind gift from Dr. Edmond LaVoie. The MDA-MB-231 breast cancer cell line is estrogen receptor negative, progesterone receptor negative, and HER-2/neu negative and from a pleural effusion of breast adenocarcinoma from a 51-year-old female (53) . The HCT-116 colorectal carcinoma cell line was from an adult male patient (54) . The HT-29 colorectal carcinoma cell line was established in 1964 from the primary tumor of a 44-year-old female (55) . The RPMI-8226 line is a B lymphocyte plasmacytoma, myeloma cell line established from a 61-year-old male (56) . The NCI-H460 large cell lung carcinoma was from the pleural effusion fluid of a male patient (57) . The KB human carcinoma cell line was originally thought to be derived from an epidermal carcinoma of the mouth but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes and DNA fingerprinting, to have been established via HeLa cell contamination (58) . The KB3-1 line was developed by subcloning the KB cell line. The KB-V1 subline was established from the KB3-1 line by continuous exposure to vinblastine (1 Ag/mL) resulting in gene amplification of mdr1 and mdr2 (59, 60) . The KB-V1 cells have more than 300-fold higher expression of mdr1 mRNA than do KB3-1 cells and are more than 100-fold less sensitive to colchicines, doxorubicin, and vinblastine than are KB3-1 cells.
For human tumor cell CFU assays, the cell lines that grow as monolayers, MDA-MB-231, HCT-116, HT-29, NCI-H460, KB3-1, and KBV-1, were grown in RPMI 1460 (Invitrogen/ Life Technologies) supplemented with 5% FBS (Invitrogen/ Life Technologies). The RPMI-8226 cell line grows in suspension. For human tumor cell CFU assays, RPMI-8226 cells were grown in 0.35% agar in DMEM/F-12 supplemented with 10% FBS over a base layer of 0.5% agar in DMEM/F-12 supplemented with 10% FBS. Human tumor cells (1 Â 10 3 ) were plated in six-well plates in medium supplemented with 5% or 10% FBS. The compounds were tested over the range from 0.01 to 100 nmol/L in half-log intervals covering 5 logs along with vehicle controls. Each compound concentration was tested in duplicate wells. Cultures were exposed to the compounds continuously for 7 days at 37jC in a humidified atmosphere of 5% carbon dioxide balance air. Each experiment was done three independent times. Colonies were defined as clusters containing z30 cells.
For the monolayer cultures, colonies were visualized by staining with a preformulated crystal violet solution (Fisher), which contained 0.41% crystal violet and 12% ethanol balance deionized water. To visualize the colonies, the medium was removed by aspiration; the monolayer was rinsed once with PBS, which was removed by aspiration. Three drops of crystal violet solution were added to each well and the six-well plate was rotated so that the crystal violet solution covered the surface area of each well. After 5 min exposure time, the wells were rinsed twice with distilled water and the colonies were visible. The IC 50 and IC 90 values were expressed as the means with lower and upper 95% confidence intervals in nanomolar concentrations.
Flow Cytometry KBV-1 and parental KB3-1 cells, HCT-116, H460, HT-29, and MDA-MB-231, were grown to subconfluence in RPMI 1460 supplemented with 10% FBS. RPMI-8226 cells were grown in the same medium in suspension. For harvesting of adherent lines, the cell culture medium was removed, cells washed once in cold PBS, the cells detached by exposure to cold Versene (PBS-EDTA) for 5 to 10 min, and cold flow cytometry buffer (PBS + 5% FBS) was added. The cell suspensions were pelleted by centrifugation (5 min at 1,200 rpm). The cells were counted and suspended in cold flow cytometry buffer (1 mL) at 10 6 cells per tube. For BCRP staining, after centrifugation at 1,200 rpm for 5 min, the supernatant was removed and the cells suspended in 80 AL cold flow buffer and 20 AL labeled primary antibody (mouse anti-human mcIgG2b antibody to BCRP-PE conjugated; eBioscience). An isotype control (mouse IgG2b PE conjugated; eBioscience) was used for comparison. The cells were incubated with the primary antibody on ice for 1 h. For MDR1 staining, the supernatant was removed and the cells were suspended in 80 AL cold flow buffer and 20 AL labeled primary antibody [mouse antihuman mcIgG2b antibody to MDR (P-glycoprotein) PE conjugated; BD]. An isotype control (mouse IgG2b PE conjugated; BD) was used for comparison. The cells were incubated with the primary antibody on ice for 1 h. All cells were then washed twice in cold flow buffer, suspended in 250 AL cold flow buffer, and analyzed using a BD FACSCalibur flow cytometer.
HumanTumor Xenografts The efficacy of ARC-111 was compared with standard anticancer drug therapy in human tumor xenograft studies.
All procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee in accordance with the Federal Animal Welfare Act (9 CFR, 1992) and conducted in an Association for Assessment and Accreditation of Laboratory Animal Careaccredited facility. nu/nu mice from Harlan were implanted s.c. with a 4 mg tumor fragment, and treatments were initiated when tumors reached 200 mm 3 . At the time the tumor volumes reached 200 mm 3 , the animals were pair-matched into treatment (n = 8-10) or control groups (n = 8-10). Compounds were prepared freshly for injection into mice. ARC-111 and irinotecan were formulated in D5W, gemcitabine was formulated in saline, and docetaxel was formulated in ethanol, CremophorDL, and saline. The doses, schedules, and routes for each compound were determined in earlier MTD studies. ARC-111 was tested on three schedules and the most effective nontoxic regimen was selected for further study.
For experiments with the human HCT-116 colon carcinoma xenograft and the human HT-29 colon carcinoma xenograft, irinotecan was administered at 60 mg/kg/d by i.v. injection into a tail vein every fourth day for three injections, and ARC-111 was administered at 0.5, 1, and 2 mg/kg/d by i.v. injection into a tail vein on alternate days three times per week for 2 weeks. ARC-111 was compared with docetaxel in the human NCI-H460 non-small cell lung carcinoma (NSCLC) xenografts. Docetaxel was administered at 20 mg/kg/d by i.v. injection into a tail vein on alternate days for three injections. ARC-111 was compared with gemcitabine in the human MiaPaCa2 pancreatic cancer xenograft. Gemcitabine was administered at 90 mg/kg/d by i.v. injection into a tail vein every third day for four injections.
Statistical Analysis Concentration-response data for bone marrow CFU-GM and human tumor cell line CFU were analyzed using a nonlinear curve fit based on the equation: y = a Â exp(b Â x). The IC 50 and IC 90 values and the 95% confidence intervals for each compound for human and Tumor volumes were calculated using the formula: (w 2 Â l) / 2, where w is the width of the tumor and l is the length of the tumor. Individual mice were weighed and tumor measurements were taken by calipers twice weekly. The data are presented as mean F SE tumor volume. Mice were euthanized when the tumors reached a predetermined volume. Antitumor activity of the compounds was determined by calculating tumor growth delay (TGD; T-C) in days at a tumor volume of 1,500 mm 3 . Increase in lifespan was determined as a secondary endpoint with removal from study due to tumor size. Fold increase in lifespan was calculated from median survival in days for the treated versus control groups. Kaplan-Meier survival curves were prepared using GraphPad Prism software and used to determine the median survival times for each group of mice.
Results
The compounds ARC-111, topotecan, and SN-38 are potent cytotoxic agents toward both mouse and human bone marrow CFU-GM. Exposure to the compounds produced killing of cells in an exponential manner. The concentration-response curves fit with a nonlinear exponential model are shown in Fig. 2 . Coefficient of determination R 2 values provides a measure of the goodness-of-fit of the data to the model (Table 1 ). For all compounds tested, concentrations killing 50% and 90% of the cells were readily achieved. Human and mouse bone marrow CFU-GM IC 50 values were 3-to 4-fold lower than the corresponding IC 90 values; thus, the concentration-response curves for these compounds are steep (Table 1) . Human bone marrow CFU-GM was more sensitive to the cytotoxicity of the compounds than was mouse bone marrow CFU-GM. ARC-111 was a more potent cytotoxic agent than the camptothecins, topotecan and SN-38 (irinotecan). The ratios of the mouse and human bone marrow CFU-GM at the IC 50 and IC 90 concentrations were calculated (Table 1) . For the camptothecins, the ratios were z10; for ARC-111, the ratios were 4 to 5.
ARC-111, topotecan, and SN-38 were potent cytotoxic agents toward human tumor cells. As in the experiments conducted with mouse bone marrow, exposure to the compounds produced exponential killing of cells. The concentration-response curves fit with a nonlinear exponential model are shown in Fig. 3 . Coefficient of determination R 2 values provides a measure of the goodness-of-fit of the data to the model (Table 2) . Concentrations killing 50% and 90% of the cells were readily achieved for all three compounds. The ratios of the IC 50 to IC 90 values were between 2.7 and 4, indicating a steep concentration (Table 2 ). ARC-111 was a more potent cytotoxic agent than the camptothecins, topotecan and SN-38 (irinotecan).
KBV-1 cells express much higher levels of MDR than parental control KB3-1 cells, and H460, HT-29, and RPMI-8226 cells are very high expressers of BCRP (Fig. 4) . Cells with high expression of either MDR or BCRP were markedly resistant killing by topotecan and SN-38 but not to killing by ARC-111 (Table 2) .
In vivo, ARC-111 was tolerated at doses up to 2 mg/kg i.v. on alternate days and these was determined to be the optimal dose and schedule for the compound. The efficacy of ARC-111 was compared with irinotecan in human HCT-116 colon cancer xenograft (Fig. 5A) . TGD values were 17 days for irinotecan and 20 days for ARC-111 (Table 3 ). The maximal body weight loss for mice in this mct.aacrjournals.org Downloaded from study was 5.4% in the irinotecan group and 10.2% in the ARC-111 (2 mg/kg) group. A similar study was done with the human HT-29 colon cancer xenograft, and the TGD was 9 days for both irinotecan and ARC-111 (Fig. 5B) . The maximal body weight loss for mice in this study was <10% for both irinotecan group and ARC-111 (2 mg/kg) group (Table 3) . ARC-111 was compared with docetaxel in human NCI-H460 NSCLC xenografts (Fig. 5C ). Docetaxel and ARC-111 administration each resulted in a TGD of about 21 days. Docetaxel produced a weight loss of 26% in mice bearing NCI-H460 tumors, whereas the maximal weight loss for mice treated with ARC-111 in this study was 10% (Table 3) . ARC-111 was compared with gemcitabine in human MiaPaCa2 pancreatic cancer xenograft (Fig. 5D) . Gemcitabine administration resulted in a TGD of 7 days as did ARC-111 (49) . The maximal body weight loss for mice in this study was less than 5% to 6%, which occurred in the gemcitabine group and ARC-111 (2 mg/kg) group (Table 3) .
Both ARC-111 (2 mg/kg) and irinotecan treatment provided a survival benefit to mice bearing HCT-116 colon carcinoma with a 1.7-fold increase in median survival from 25 to 42 days. There was only a modest 1.3-fold survival benefit on treatment of HT-29 colon carcinoma bearing mice with ARC-111 (2 mg/kg) or irinotecan from a median survival of 46 days to 58 to 59 days. ARC-111 (2 mg/kg) and docetaxel provided a survival benefit to mice bearing NCI-H460 NSCLC. Treatment with ARC-111 (2 mg/kg) increased median survival from 25 to 45 days, a 1.8-fold increase, whereas docetaxel increased survival from 25 to 42 days, a 1.7-fold increase, albeit with profound weight loss (Table 3) . Finally, ARC-111 (2 mg/kg) and gemcitabine provided a modest survival benefit to mice bearing MiaPaCa2 pancreatic carcinoma of 1.2-to 1.3-fold increase in median survival time.
Discussion
Bone marrow CFU-GM assays comparing the sensitivity of bone marrows across species have been useful in predicting the blood levels of agents that might be reached in patients compared with blood levels in preclinical efficacy and safety species (50) . The bone marrow toxicity of three TopoI inhibitors was examined (Table 1; refs. 49 -52) . Although human and canine bone marrow may have similar sensitivity to TopoI inhibitors, we found that murine bone marrow is 4.5-to 27-fold less sensitive to these compounds. The differential sensitivity between murine and human bone marrow progenitor cells to TopoI inhibitors may explain, in part, why curative doses/blood levels of topotecan and irinotecan/SN-38 in mice with human tumor xenografts are not achievable in patients (51, 52) . The corollary is that compounds with smaller or no differential in bone marrow progenitor sensitivity among species would likely have a better potential for reaching similar blood levels in patients as in mice. If bone marrow toxicity is dose-limiting in humans, these compounds would more likely be successful in reaching therapeutic doses. From these data, ARC-111 would be predicted to be most promising. It is possible that a compound with lower bone marrow differential that may have clinical potential but could be a human tumor xenograft failure-the paradigm works both ways. ARC-111 appears to pass both tests.
Working only from the in vitro data on Tables 1 and 2 , the conclusion might be that irinotecan/SN-38 would be the most promising of the agents tested because, in most cases, the IC 90 concentrations for SN-38 in the human tumor cell lines are lower that than the IC 90 concentration in human bone marrow CFU-GM. Indeed, if irinotecan/SN-38 and their anionic forms did not suffer from the biliary excretion that contributes to the intestinal side affects of irinotecan, especially the unpredictable severe diarrhea, this agent would likely be a better drug (39) . Thus, if bone marrow toxicity were dose-limiting, irinotecan would likely have an improved therapeutic index. However, in the selection of compounds for clinical development, the comparison between doses of compound achievable in the mouse with that achievable in patients has been difficult to anticipate; therefore, the ratio of human to mouse bone marrow CFU-GM may be useful. Pessina (50) went further to suggest that, through use of the ratio between mouse and human CFU-GM IC 90 values as well as the maximum tolerated dose of the compound in mice, the maximum tolerated dose of the compound in patients could be predicted and a therapeutic blood level in patients was estimated.
Many additional variables can affect the translation of these findings to the clinical setting. For example, the difference in binding affinity of the camptothecin E ring hydroxy acid open form between mouse albumin and human albumin. In humans, this albumin protein binding acts as an inactivating mechanism and explains why mouse xenograft studies overpredict for antitumor activity of camptothecins (61) . The carboxylate form of camptothecins bind very tightly to human serum albumin and the lactone forms bind with moderate affinity to human serum albumin. The MethoCult medium used for human bone marrow cell growth contains 1% bovine serum albumin and 30% FBS, which will not accurately reflect the strong protein binding of camptothecins in human patients. Hence, without the use of human serum albumin in the cell culture medium for the camptothecins, the ability of these in vitro assays to predict myelotoxicity for camptothecins may be limited (61) . Secondly, if bone marrow toxicity is not dose-limiting in patients, this scenario does not apply.
Several strategies are being explored to develop improved TopoI inhibitors (62) . Homocamptothecins, in which the metabolically labile camptothecin lactone is replaced with a more stable seven-membered h-hydroxylactone, are potent anticancer agents. Gimatecan is a seven-position modified lipophilic camptothecin developed to provide rapid uptake and accumulation in cells and a stable TopoI-DNA-drug ternary complex. Diflomotecan, a homocamptothecin, and gimatecan are in phase II clinical trial. Among noncamptothecins, edotecarin, an indolocarbazole that results in DNA C/T-G cleavage compared with T-G/A for camptothecins, is in phase II clinical trial. Indenoisoquinolines were identified as TopoI inhibitors by the NCI-60 cell line COMPARE analysis. Cocrystal structures of two indenoisoquinolines with TopoI-DNA elucidated the structure of the ternary complex. Indenoisoquinolines are in preclinical development.
Dibenzonaphthyridinone TopoI inhibitors have undergone extensive structure-activity examination. The cytotoxicity of ARC-111 was assessed in seven human tumor cell lines of varied histology and resistance mechanisms by colony formation. Compared with topotecan and SN-38, ARC-111 was a more potent cytotoxic agent and was highly effective in cells expressing efflux pumps. Meng et al. (63) reported that, like other TopoI inhibitors, the antiproliferative effects of ARC-111 were oxygen independent, which is distinguishable from inhibition of hypoxia-inducible factor-1aaccumulation by ARC-111, only observed under hypoxia and supporting the potential anticancer effect of ARC-111 on hypoxic tumors. ARC-111 was shown to be an effective antitumor agent against several standard human tumor xenografts. ARC-111 was as active as irinotecan in the HCT-8 colon carcinoma and as active as topotecan or irinotecan in the SKNEP anaplastic Wilm's xenograft (47) . ARC-111 was also a very effective antitumor agent in animals bearing the SJ-BT45 medulloblastoma (48) . In the current study, ARC-111 was as or more effective as an anticancer agent than was irinotecan, docetaxel, or gemcitabine in several human tumor xenograft models.
TopoI inhibitors are active and effective anticancer drugs, although the currently Food and Drug Administrationapproved TopoI inhibitors are molecules that can be improved upon. For these reasons, TopoI remains a target , alternate days for 2 wk; E), ARC-111 (2 mg/kg i.v., alternate days for 2 wk; n), and irinotecan (60 mg/kg i.v., each fourth day for three injections; n). C, NCI-H460 NSCLC untreated controls (*), ARC-111 vehicle treated (*), docetaxel vehicle treated (E), ARC-111 (0.5 mg/kg i.v., alternate days for 2 wk; n), ARC-111 (1 mg/kg i.v., alternate days for 2 wk; o), ARC-111 (2 mg/kg i.v., alternate days for 2 wk; 5), and docetaxel (20 mg/kg i.v., alternate days for three injections; 4). D, MiaPaCa2 pancreatic carcinoma ARC-111 vehicle treated (*), gemcitabine vehicle treated (*), ARC-111 (0.5 mg/kg i.v., alternate days for 2 wk; E), ARC-111 (1 mg/kg i.v., alternate days for 2 wk; n), ARC-111 (2 mg/kg i.v., alternate days for 2 wk; o), and gemcitabine (90 mg/kg i.v., every third day for four injections; x). X axis, 2-wk treatment time with ARC-111. Mean F SE for groups of 8 to 10 mice.
of active interest in the development new anticancer agents. There are currently both camptothecin and noncamptothecin TopoI inhibitors in preclinical and clinical development. Each of these investigational molecules may have properties that lead to improved therapeutic benefit to patients (62) . There is an active search in the TopoI inhibitor field for biomarkers such as gene signatures or markers based on protein phosphorylation and mRNA levels in tumor or blood samples. The hope is to identify biomarkers that can select patients most likely to benefit from treatment with TopoI inhibitors and aid in defining the lowest effective dose and appropriate schedule of administration of these agents. The convergence of these efforts should result in a second-generation TopoI inhibitors that are highly clinically effective for the treatment of malignant disease in patients. 
Disclosure of Potential Conflicts of Interest
